Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos Sells 10,964 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares of the company’s stock, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock opened at $9.85 on Thursday. The stock’s 50-day moving average is $9.22 and its 200 day moving average is $8.47. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $14.45.

Analyst Ratings Changes

VIR has been the topic of several analyst reports. Leerink Partners boosted their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research report on Wednesday, November 20th. JPMorgan Chase & Co. raised their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Barclays reduced their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.83.

Hedge Funds Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. boosted its position in shares of Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after purchasing an additional 2,351 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vir Biotechnology during the 4th quarter worth approximately $42,000. nVerses Capital LLC bought a new position in Vir Biotechnology in the third quarter worth approximately $56,000. SBI Securities Co. Ltd. acquired a new stake in Vir Biotechnology in the fourth quarter valued at approximately $60,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Vir Biotechnology by 31.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,999 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).